- Home
- PDI vs ROIV Comparison
PDI vs ROIV Comparison
Compare PDI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDI
- ROIV
- Stock Information
- Founded
- PDI 2012
- ROIV 2014
- Country
- PDI United States
- ROIV United Kingdom
- Employees
- PDI N/A
- ROIV N/A
- Industry
- PDI Trusts Except Educational Religious and Charitable
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- PDI Finance
- ROIV Health Care
- Exchange
- PDI Nasdaq
- ROIV Nasdaq
- Market Cap
- PDI 7.6B
- ROIV 8.6B
- IPO Year
- PDI N/A
- ROIV N/A
- Fundamental
- Price
- PDI $19.96
- ROIV $16.14
- Analyst Decision
- PDI
- ROIV Strong Buy
- Analyst Count
- PDI 0
- ROIV 8
- Target Price
- PDI N/A
- ROIV $19.94
- AVG Volume (30 Days)
- PDI 1.5M
- ROIV 9.5M
- Earning Date
- PDI 01-01-0001
- ROIV 11-11-2025
- Dividend Yield
- PDI 13.81%
- ROIV N/A
- EPS Growth
- PDI N/A
- ROIV N/A
- EPS
- PDI N/A
- ROIV N/A
- Revenue
- PDI N/A
- ROIV $23,233,000.00
- Revenue This Year
- PDI N/A
- ROIV N/A
- Revenue Next Year
- PDI N/A
- ROIV $248.22
- P/E Ratio
- PDI N/A
- ROIV N/A
- Revenue Growth
- PDI N/A
- ROIV N/A
- 52 Week Low
- PDI $15.45
- ROIV $8.73
- 52 Week High
- PDI $19.60
- ROIV $16.79
- Technical
- Relative Strength Index (RSI)
- PDI 69.10
- ROIV 77.88
- Support Level
- PDI $19.63
- ROIV $14.86
- Resistance Level
- PDI $19.90
- ROIV $16.79
- Average True Range (ATR)
- PDI 0.08
- ROIV 0.47
- MACD
- PDI -0.01
- ROIV 0.05
- Stochastic Oscillator
- PDI 99.03
- ROIV 72.27
About PDI PIMCO Dynamic Income Fund
PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investments include mortgage-backed securities, investment grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.